Table 4.
Per unit risk in transfused RBC under current donor testing protocols in the United States
| Pathogen | Risk | Method of estimation |
|---|---|---|
| Higher‐risk pathogens | ||
| B. microti 27 |
0.076% (1 in 1316) |
Antibody and PCR data in endemic areasaunder IND screeningb |
| CMV1, 46 |
0.1% (1 in 1000)a |
Detection of infection in transfused recipients and PCR data in donors |
| EIA | ||
| Acute‐type agent4 |
0.025% (1 in 4000) |
Mathematical modelingc |
| Chronic‐type agent4 |
0.045% (1 in 2222) |
Mathematical modelingc |
| Lower‐risk pathogens | ||
| Plasmodia—all species | Rare | Clinical case reporting (<1 TT case per year in United States) |
| Bacteria33 |
0.00005% (1 in 2 million) Clinical Sepsis |
Based on French and German Data No documented clinical cases in the United States in past 5 years; May be more common for subclinical cases |
| A. phagocytophilum 50, 51 | Rare |
Clinical case reporting (<1 TT case per year in United States); May be more common for subclinical cases |
| HIV63 |
0.00007% (1 in 1.5 million) |
Mathematical modelingd |
| HCV63 |
0.00009% (1 in 1.1 million) |
Mathematical modelingd |
| HBV64 |
0.0001% (1 in 1 million) |
Mathematical modelingd |
| WNV65 | Rare | Clinical case reporting (<1 TT case per year in United States) |
Rare in nonendemic areas.
Assumes that all PCR‐positive donations, regardless of antibody status, would be infectious.
Using data from previously detected EIAs.
Using NAT donor screening data and a window period model.
IND = investigational new drug.